Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

ERR2208930

—

dc9e61cd-2500-59df-83cd-a5237169282a

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • BILE_ACID_METABOLISM+0.400
  • ESTROGEN_RESPONSE_EARLY+0.400
  • ESTROGEN_RESPONSE_LATE+0.400
  • KRAS_SIGNALING_DN+0.400
  • MYOGENESIS+0.400
  • APICAL_JUNCTION+0.300
  • APICAL_SURFACE+0.300
  • CHOLESTEROL_HOMEOSTASIS+0.300
  • FATTY_ACID_METABOLISM+0.300
  • XENOBIOTIC_METABOLISM+0.300

Top 10 suppressed

  • E2F_TARGETS-0.700
  • G2M_CHECKPOINT-0.600
  • INTERFERON_ALPHA_RESPONSE-0.600
  • MYC_TARGETS_V1-0.600
  • DNA_REPAIR-0.500
  • MYC_TARGETS_V2-0.500
  • UNFOLDED_PROTEIN_RESPONSE-0.500
  • INTERFERON_GAMMA_RESPONSE-0.400
  • MITOTIC_SPINDLE-0.400
  • PROTEIN_SECRETION-0.400

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

6 twins match this tumor's tissue · 4 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1c52d39b7-3811-41e5-bdc8-9ed59632a903
melanoma-umap@29
——0.915
2s0112300
melanoma-umap@29
——0.907
3SRR1409305
brain-umap@2
GTEX—0.894
4GSM6454739
breast-umap@18
—A0.870
5BS_MKP2Y41Z
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.869
6C3L-01890
lung-landscapes@6
—cohortA20.868
7SRR1405485
brain-umap@2
GTEX—0.858
8BS_AKRHBPNZ
brain-umap@2
Ganglioglioma—0.856
9aMVAC.P_003_TURBT_S220
bladder-landscape@3
——0.856
10SRR1313113
breast-umap@18
—A0.855

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 23 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
BILE_ACID_METABOLISM0.400Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.400Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.400Idelalisib— uncovered
KRAS_SIGNALING_DN0.400Remibrutinib— uncovered
MYOGENESIS0.400Inavolisib— uncovered
APICAL_JUNCTION0.300Inavolisib— uncovered
APICAL_SURFACE0.300Temsirolimus— uncovered
CHOLESTEROL_HOMEOSTASIS0.300Remibrutinib— uncovered
FATTY_ACID_METABOLISM0.300Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.300Inavolisib— uncovered
ADIPOGENESIS0.200Inavolisib— uncovered
COAGULATION0.200Binimetinib— uncovered
PEROXISOME0.200Idelalisib— uncovered
UV_RESPONSE_DN0.200Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.200Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.100Inavolisib— uncovered
HEDGEHOG_SIGNALING0.100Inavolisib— uncovered
HEME_METABOLISM0.100Temsirolimus— uncovered
HYPOXIA0.100Idelalisib— uncovered
KRAS_SIGNALING_UP0.100Inavolisib— uncovered